High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving AMRUBICIN (cas 110267-81-7)

Add time:08/08/2019    Source:sciencedirect.com

ObjectivesAmrubicin monotherapy is a treatment option for patients with relapsed small cell lung cancers (SCLCs). Topoisomerase-II (Topo-II) – a target of amrubicin – has been reported as a predictive or prognostic marker for chemosensitivity or outcomes in patients with various malignancies. Here, we investigated the prognostic role of Topo-II expression in patients with relapsed SCLCs who underwent amrubicin monotherapy.

We also recommend Trading Suppliers and Manufacturers of AMRUBICIN (cas 110267-81-7). Pls Click Website Link as below: cas 110267-81-7 suppliers

Prev:Synthesis, characterization, molecular docking, ADME and biological evaluation of 3-(4-(tetrazol-1-yl)phenyl)-5-phenyl-1H-pyrazoles
Next:AMRUBICIN (cas 110267-81-7) and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium)